Ketamine, Transcranial Magnetic Stimulation, and Depression Specific Yoga and Mindfulness Based Cognitive Therapy in Management of Treatment Resistant Depression: Review and Some Data on Efficacy

Basant Pradhan, Tapan Parikh, Ramkrishna Makani, Madhusmita Sahoo, Basant Pradhan, Tapan Parikh, Ramkrishna Makani, Madhusmita Sahoo

Abstract

Depression affects about 121 million people worldwide and prevalence of major depressive disorder (MDD) in US adults is 6.4%. Treatment resistant depression (TRD) accounts for approximately 12-20% of all depression patients and costs $29-$48 billion annually. Ketamine and repetitive transcranial magnetic stimulation (rTMS) have useful roles in TRD, but their utility in long term is unknown. As per the latest literature, the interventions using Yoga and meditation including the mindfulness based cognitive therapy (MBCT) have been useful in treatment of depression and relapse prevention. We present a review of rTMS, ketamine, and MBCT and also report efficacy of a depression specific, innovative, and translational model of Yoga and mindfulness based cognitive therapy (DepS Y-MBCT), developed by the first author. DepS Y-MBCT as an adjunctive treatment successfully ameliorated TRD symptoms in 27/32 patients in an open label pilot trial in TRD patients. Considering the limitations of existing treatment options, including those of ketamine and rTMS when used as the sole modality of treatment, we suggest a "tiered approach for TRD" by combining ketamine and rTMS (alone or along with antidepressants) for rapid remission of acute depression symptoms and to use DepS Y-MBCT for maintaining remission and preventing relapse.

Figures

Figure 1
Figure 1
Depression specific Yoga and mindfulness based cognitive therapy (DepS Y-MBCT) model.

References

    1. Kavalali E. T., Monteggia L. M. Synaptic mechanisms underlying rapid antidepressant action of ketamine. American Journal of Psychiatry. 2012;169(11):1150–1156. doi: 10.1176/appi.ajp.2012.12040531.
    1. McIntyre R. S., Filteau M.-J., Martin L., et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders. 2014;156:1–7. doi: 10.1016/j.jad.2013.10.043.
    1. Mrazek D. A., Hornberger J. C., Altar C. A., Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatric Services. 2014;65(8):977–987. doi: 10.1176/appi.ps.201300059.
    1. Zarate C., Duman R. S., Liu G., Sartori S., Quiroz J., Murck H. New paradigms for treatment-resistant depression. Annals of the New York Academy of Sciences. 2013;1292(1):21–31. doi: 10.1111/nyas.12223.
    1. Ruhé H. G., Huyser J., Swinkels J. A., Schene A. H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. Journal of Clinical Psychiatry. 2006;67(12):1836–1855. doi: 10.4088/jcp.v67n1203.
    1. Sackeim H. A. The definition and meaning of treatment-resistant depression. Journal of Clinical Psychiatry. 2001;62(supplement 16):10–17.
    1. Connolly K. R., Thase M. E. Emerging drugs for major depressive disorder. Expert Opinion on Emerging Drugs. 2012;17(1):105–126. doi: 10.1517/14728214.2012.660146.
    1. Birkenhäger T. K., Ruhé H. G. The pharmacological frontiers in treatment resistant major depression. In: Schoepf D., editor. Psychiatric Disorders-New Frontiers in Affective Disorders. Morn Hill, UK: InTech; 2013.
    1. Cusin C., Dougherty D. D. Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS. Biology of Mood & Anxiety Disorders. 2012;2, article 14 doi: 10.1186/2045-5380-2-14.
    1. Cook I. A., Espinoza R., Leuchter A. F. Neuromodulation for depression: invasive and noninvasive (deep brain stimulation, transcranial magnetic stimulation, trigeminal nerve stimulation) Neurosurgery Clinics of North America. 2014;25(1):103–116. doi: 10.1016/j.nec.2013.10.002.
    1. Shah A., Carreno F. R., Frazer A. Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine. Clinical Psychopharmacology and Neuroscience. 2014;12(2):83–93. doi: 10.9758/cpn.2014.12.2.83.
    1. Pradhan B., Sharma A. The time has come for integrating complementary medicine into psychiatry. Adolescent Psychiatry. 2015;5(2):71–72.
    1. Pradhan B. Depression specific Yoga and mindfulness based cognitive therapy (DepS Y-MBCT) model: description, data on efficacy and differences from contemporary models. In: Greenblatt J., Brogan K., editors. Integrative Psychiatry for Depression: Redefining Models for Assessment, Treatment, and Prevention of Mood Disorders. Boca Raton, Fla, USA: Taylor & Francis Group; 2015.
    1. Dwyer J. M., Duman R. S. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biological Psychiatry. 2013;73(12):1189–1198. doi: 10.1016/j.biopsych.2012.11.011.
    1. Naughton M., Clarke G., Oleary O. F., Cryan J. F., Dinan T. G. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Journal of Affective Disorders. 2014;156:24–35. doi: 10.1016/j.jad.2013.11.014.
    1. Malkesman O., Austin D. R., Tragon T., et al. Acute D-serine treatment produces antidepressant-like effects in rodents. International Journal of Neuropsychopharmacology. 2012;15(8):1135–1148. doi: 10.1017/s1461145711001386.
    1. Li N., Lee B., Liu R.-J., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964. doi: 10.1126/science.1190287.
    1. Duman C. H., Duman R. S. Spine synapse remodeling in the pathophysiology and treatment of depression. Neuroscience Letters. 2015;601:20–29. doi: 10.1016/j.neulet.2015.01.022.
    1. Fuchikami M., Thomas A., Liu R., et al. Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions. Proceedings of the National Academy of Sciences. 2015;112(26):8106–8111. doi: 10.1073/pnas.1414728112.
    1. Andreasen J. T., Redrobe J. P., Nielsen E. Ø. Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. Pharmacology Biochemistry and Behavior. 2012;100(3):624–629. doi: 10.1016/j.pbb.2011.11.004.
    1. Berman R. M., Cappiello A., Anand A., et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry. 2000;47(4):351–354. doi: 10.1016/S0006-3223(99)00230-9.
    1. Messer M., Haller I. V., Larson P., Pattison-Crisostomo J., Gessert C. E. The use of a series of ketamine infusions in two patients with treatment-resistant depression. Journal of Neuropsychiatry and Clinical Neurosciences. 2010;22(4):442–444. doi: 10.1176/appi.neuropsych.22.4.442.
    1. Valentine G. W., Mason G. F., Gomez R., et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Research: Neuroimaging. 2011;191(2):122–127. doi: 10.1016/j.pscychresns.2010.10.009.
    1. Murrough J. W., Iosifescu D. V., Chang L. C., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. American Journal of Psychiatry. 2013;170(10):1134–1142. doi: 10.1176/appi.ajp.2013.13030392.
    1. DiazGranados N., Ibrahim L. A., Brutsche N. E., et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychiatry. 2010;71(12):1605–1611. doi: 10.4088/JCP.09m05327blu.
    1. Zarate C. A., Brutsche N., Laje G., et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biological Psychiatry. 2012;72(4):331–338. doi: 10.1016/j.biopsych.2012.03.004.
    1. Inoue K. Cognitive-behavioral therapy for treatment-resistant depression. Seishin Shinkeigaku Zasshi. 2010;112(11):1097–1104.
    1. Ibrahim L., Diazgranados N., Franco-Chaves J., et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012;37(6):1526–1533. doi: 10.1038/npp.2011.338.
    1. Murrough J. W., Perez A. M., Pillemer S., et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry. 2013;74(4):250–256. doi: 10.1016/j.biopsych.2012.06.022.
    1. Rot M. A. H., Zarate C. A., Jr., Charney D. S., Mathew S. J. Ketamine for depression: where do we go from here? Biological Psychiatry. 2012;72(7):537–547. doi: 10.1016/j.biopsych.2012.05.003.
    1. Diamond P. R., Farmery A. D., Atkinson S., et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. Journal of Psychopharmacology. 2014;28(6):536–544. doi: 10.1177/0269881114527361.
    1. Aan het Rot M., Collins K. A., Murrough J. W., et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry. 2010;67(2):139–145. doi: 10.1016/j.biopsych.2009.08.038.
    1. Loo C. K., Katalinic N., Garfield J. B. B., Sainsbury K., Hadzi-Pavlovic D., Mac-Pherson R. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. Journal of Affective Disorders. 2012;142(1–3):233–240. doi: 10.1016/j.jad.2012.04.032.
    1. Yoosefi A., Sepehri A. S., Kargar M., et al. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. The Journal of ECT. 2014;30(1):15–21. doi: 10.1097/yct.0b013e3182a4b4c6.
    1. Gregory-Roberts E. M., Naismith S. L., Cullen K. M., Hickie I. B. Electroconvulsive therapy-induced persistent retrograde amnesia: could it be minimised by ketamine or other pharmacological approaches? Journal of Affective Disorders. 2010;126(1-2):39–45. doi: 10.1016/j.jad.2009.11.018.
    1. Price R. B., Nock M. K., Charney D. S., Mathew S. J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biological Psychiatry. 2009;66(5):522–526. doi: 10.1016/j.biopsych.2009.04.029.
    1. Dakwar E., Levin F., Foltin R. W., Nunes E. V., Hart C. L. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biological Psychiatry. 2014;76(1):40–46. doi: 10.1016/j.biopsych.2013.08.009.
    1. Reinstatler L., Youssef N. A. Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs in R and D. 2015;15(1):37–43. doi: 10.1007/s40268-015-0081-0.
    1. Zarate C. A. J., Wainer I. W. Ketamine-response in PTSD not apparent until 24-hrs post infusion. 2013.
    1. Aan het Rot M., Charney D. S., Mathew S. J. Intravenous ketamine for treatment-resistant major depressive disorder. Primary Psychiatry. 2008;15(4):39–47.
    1. Pradhan B. K., D'Amico J. K., Makani R., Parikh T. Nonconventional interventions for chronic post-traumatic stress disorder (PTSD): ketamine, repetitive trans-cranial magnetic stimulation (rTMS) and alternative approaches. Journal of Trauma & Dissociation. 2015 doi: 10.1080/15299732.2015.1046101.
    1. Zigman D., Blier P. Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report. Journal of Clinical Psychopharmacology. 2013;33(2):270–272. doi: 10.1097/jcp.0b013e3182856865.
    1. Luckenbaugh D. A., Niciu M. J., Ionescu D. F., et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders. 2014;159:56–61. doi: 10.1016/j.jad.2014.02.017brief.
    1. Green S. M., Johnson N. E. Ketamine sedation for pediatric procedures. Part 2. Review and implications. Annals of Emergency Medicine. 1990;19(9):1033–1046. doi: 10.1016/s0196-0644(05)82569-7.
    1. Preskorn S. H., Baker B., Kolluri S., Menniti F. S., Krams M., Landen J. W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology. 2008;28(6):631–637. doi: 10.1097/jcp.0b013e31818a6cea.
    1. Murrough J. W., Wan L.-B., Iacoviello B., et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology. 2014;231(3):481–488. doi: 10.1007/s00213-013-3255-x.
    1. Sos P., Klirova M., Novak T., Kohutova B., Horacek J., Palenicek T. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinology Letters. 2013;34(4):287–293.
    1. Morgan C. J. A., Riccelli M., Maitland C. H., Curran H. V. Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. Drug and Alcohol Dependence. 2004;75(3):301–308. doi: 10.1016/j.drugalcdep.2004.03.006.
    1. Ciobanu C., Girard M., Marin B., Labrunie A., Malauzat D. rTMS for pharmacoresistant major depression in the clinical setting of a psychiatric hospital: effectiveness and effects of age. Journal of Affective Disorders. 2013;150(2):677–681. doi: 10.1016/j.jad.2013.03.024.
    1. Harel E. V., Rabany L., Deutsch L., Bloch Y., Zangen A., Levkovitz Y. H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: an 18-week continuation safety and feasibility study. World Journal of Biological Psychiatry. 2014;15(4):298–306. doi: 10.3109/15622975.2011.639802.
    1. Dunner D. L., Aaronson S. T., Sackeim H. A., et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry. 2014;75(12):1394–1401. doi: 10.4088/JCP.13m08977.
    1. Kedzior K. K., Rajput V., Price G., Lee J., Martin-Iverson M. Cognitive correlates of repetitive transcranial magnetic stimulation (rTMS) in treatment-resistant depression—a pilot study. BMC Psychiatry. 2012;12, article 163 doi: 10.1186/1471-244x-12-163.
    1. Gaynes B. N., Lloyd S. W., Lux L., et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. Journal of Clinical Psychiatry. 2014;75(5):477–489. doi: 10.4088/jcp.13r08815.
    1. Donaldson A. E., Gordon M. S., Melvin G. A., Barton D. A., Fitzgerald P. B. Addressing the needs of adolescents with treatment resistant depressive disorders: a systematic review of rTMS. Brain Stimulation. 2014;7(1):7–12. doi: 10.1016/j.brs.2013.09.012.
    1. Zhang Y. Q., Zhu D., Zhou X. Y., et al. Bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. Brazilian Journal of Medical and Biological Research. 2015;48(3):198–206.
    1. Liu B., Zhang Y., Zhang L., Li L. Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study. BMC Psychiatry. 2014;14(1, article 342) doi: 10.1186/s12888-014-0342-4.
    1. Janicak P. G., Dokucu M. E. Transcranial magnetic stimulation for the treatment of major depression. Neuropsychiatric Disease and Treatment. 2015;11:1549–1560. doi: 10.2147/NDT.S67477.
    1. Serafini G., Pompili M., Belvederi Murri M., et al. The effects of repetitive transcranial magnetic stimulation on cognitive performance in treatment-resistant depression. A systematic review. Neuropsychobiology. 2015;71(3):125–139. doi: 10.1159/000381351.
    1. Dodick D. W., Schembri C. T., Helmuth M., Aurora S. K. Transcranial magnetic stimulation for migraine: a safety review. Headache. 2010;50(7):1153–1163. doi: 10.1111/j.1526-4610.2010.01697.x.
    1. Connolly K. R., Helmer A., Cristancho M. A., Cristancho P., O'Reardon J. P. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the united states: results observed with the first 100 consecutive cases of depression at an academic medical center. Journal of Clinical Psychiatry. 2012;73(4):e567–e573. doi: 10.4088/jcp.11m07413.
    1. Cristancho M. A., Cristancho P., O'reardon J. P. Aminoff. Brain Stimulation: Handbook of Clinical Neurology. chapter 34. Vol. 116. Elsevier; 2013. Other therapeutic psychiatric uses of superficial brain stimulation; pp. 415–422.
    1. Buddhaghosha B. Visuddhimagga (The Path of Purification) Berkeley, Calif, USA: Sambhala; (English Translations by B. Nyanamoli). 1976 (Pali)
    1. Pradhan B., Gray R., Parikh T., Akkireddi P., Pumariega A. Trauma interventions using mindfulness based extinction and reconsolidation (TIMBER) as monotherapy for chronic PTSD: a pilot study. Adolescent Psychiatry. 2015;5(2):125–131. doi: 10.2174/221067660502150430155038.
    1. Pradhan B. K., Pumariega A. J., Barnes A. Successful use of mindfulness based graded exposure therapy (M-BET) in adolescents with PTSD: a case series. Proceedings of the 21st World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP '14); 2014; Durban, South Africa.
    1. Pradhan B. Yoga and Mindfulness Based Cognitive Therapy: A Clinical Guide. Berlin, Germany: Springer; 2014.
    1. Balasubramaniam M., Telles S., Doraiswamy P. M. Yoga on our minds: a systematic review of yoga for neuropsychiatric disorders. Frontiers in Psychiatry. 2013;3, article 117 doi: 10.3389/fpsyt.2012.00117.
    1. Felder J. N., Dimidjian S., Segal Z. Collaboration in mindfulness-based cognitive therapy. Journal of Clinical Psychology. 2012;68(2):179–186. doi: 10.1002/jclp.21832.
    1. Ludwig D. S., Kabat-Zinn J. Mindfulness in medicine. The Journal of the American Medical Association. 2008;300(11):1350–1352. doi: 10.1001/jama.300.11.1350.
    1. Segal Z. V., Williams J. M., Teasdale J. D. Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse. New York, NY, USA: Guilford Press; 2002.
    1. Segal Z. V., Williams J. M. G., Teasdale J. D. Mindfulness-Based Cognitive Therapy for Depression. Guilford Press; 2012.
    1. Teasdale J. D., Moore R. G., Hayhurst H., Pope M., Williams S., Segal Z. V. Metacognitive awareness and prevention of relapse in depression: empirical evidence. Journal of Consulting and Clinical Psychology. 2002;70(2):275–287. doi: 10.1037//0022-006x.70.2.275.
    1. Piet J., Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clinical Psychology Review. 2011;31(6):1032–1040. doi: 10.1016/j.cpr.2011.05.002.
    1. Nyanaponika T. The Heart of Buddhist Meditation. York Beach, Me, USA: Samuel Weiser Publishers; 1965.
    1. Kahl K. G., Winter L., Schweiger U. The third wave of cognitive behavioural therapies: what is new and what is effective? Current Opinion in Psychiatry. 2012;25(6):522–528. doi: 10.1097/yco.0b013e328358e531.
    1. Zimmerman M., Martinez J. H., Young D., Chelminski I., Dalrymple K. Severity classification on the hamilton depression rating scale. Journal of Affective Disorders. 2013;150(2):384–388. doi: 10.1016/j.jad.2013.04.028.
    1. Rush A. J. Ketamine for treatment-resistant depression: ready or not for clinical use? The American Journal of Psychiatry. 2013;170(10):1079–1081. doi: 10.1176/appi.ajp.2013.13081034.
    1. Streeter C. C., Theodore H. Whitfield, Owen L., et al. Effects of yoga versus walking on mood, anxiety, and brain GABA levels: a randomized controlled MRS Study. Journal of Alternative and Complementary Medicine. 2010;16(11):1145–1152. doi: 10.1089/acm.2010.0007.
    1. Streeter C. C., Jensen J. E., Perlmutter R. M., et al. Yoga Asana sessions increase brain GABA levels: a pilot study. Journal of Alternative and Complementary Medicine. 2007;13(4):419–426. doi: 10.1089/acm.2007.6338.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel